Dr. John A. Spertus, M.D.
Cardiology (Cardiovascular Disease Physician)
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of California, San Francisco School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MO license 111506
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Truman Medical Center Hospital Hill Kansas City, MO
Medical groups
- University Health Physicians (350 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $166 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $139 |
|---|---|
| Amneal Pharmaceuticals LLC | $27.44 |
| Food and Beverage | $166 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $87,375 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Janssen Scientific Affairs, LLC - TWIST II Pivotal Study 2025-03
Edwards Lifesciences Corporation - CLASP II TR Pivotal, Study No. 2019-07
Edwards Lifesciences Corporation - TRISCEND II Pivotal Trial 2020-05 CONTINUED ACCESS STUDY
Edwards Lifesciences Corporation - ALT-FLOW II 2022-06
Edwards Lifesciences Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.